Structural brain MRI — measuring hippocampal atrophy, cortical thickness, and white matter changes that provide neurodegeneration evidence in Alzheimer's disease assessment — remains an essential component of AD diagnostic workup, with the Alzheimer's Disease Diagnostic Market reflecting structural imaging as foundational AD diagnostic infrastructure.

Hippocampal volumetry in AD diagnosis — the quantitative measurement of hippocampal volume from structural MRI demonstrating AD-characteristic early medial temporal lobe atrophy — provides the neurodegeneration component of the ATN biomarker framework. NeuroQuant, FreeSurfer, and various automated volumetry platforms providing standardized hippocampal volume normative comparison have enabled systematic volumetric analysis in clinical practice beyond purely visual assessment.

ARIA monitoring MRI requirements — the protocol MRI screening and safety monitoring required for patients receiving lecanemab (Leqembi) and donanemab for amyloid-related imaging abnormalities (ARIA) — has created a new clinical MRI demand category directly linked to AD drug approvals. Monthly MRI monitoring during initial dosing periods for ARIA detection in patients receiving amyloid-targeting immunotherapy creates sustained MRI demand from the treatment monitoring protocol.

White matter hyperintensity assessment — the quantification of white matter changes from small vessel cerebrovascular disease that commonly coexists with AD pathology and influences diagnosis and treatment eligibility — represents an important MRI assessment component in the AD diagnostic workup. ARIA risk stratification for amyloid therapy candidates considers existing white matter hyperintensity burden as a safety risk factor, making systematic white matter assessment clinically important for treatment eligibility.

Do you think ARIA monitoring requirements for amyloid-targeting therapies will become one of the largest drivers of brain MRI volume growth in the next five years?

FAQ

What is hippocampal volumetry in Alzheimer's diagnosis? Hippocampal volumetry uses software to automatically segment and measure hippocampal volume from structural MRI; hippocampal atrophy is among the earliest AD structural changes; volumetry results are compared to age-normalized reference databases to assess degree of atrophy; NeuroQuant (CorTechs) is an FDA-cleared volumetry platform providing automated hippocampal and regional brain volume measurements; volumetry provides the N (neurodegeneration) biomarker component in the ATN framework.

What is ARIA in Alzheimer's drug treatment? ARIA (Amyloid-Related Imaging Abnormalities) are MRI-detected brain changes occurring in patients treated with amyloid-targeting antibodies; ARIA-E (edema/effusions) appears as hyperintense areas on FLAIR MRI; ARIA-H (microhemorrhages/hemosiderin deposits) appears as hypointense areas on gradient echo MRI; ARIA occurs in approximately twenty to forty percent of treated patients depending on APOE4 status and antibody; most ARIA is asymptomatic and resolves; severe symptomatic ARIA requires treatment interruption; protocols require screening and monitoring MRI during treatment.

#AlzheimersDiagnostic #BrainMRIAlzheimers #HippocampalVolume #ARIAmonitoring #StructuralMRIAD #ADimagingMRI